Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBT (2017 - 2025)

UroGen Pharma's EBT history spans 9 years, with the latest figure at -$26.6 million for Q4 2025.

  • For Q4 2025, EBT rose 23.59% year-over-year to -$26.6 million; the TTM value through Dec 2025 reached -$153.4 million, down 23.68%, while the annual FY2025 figure was -$153.4 million, 23.68% down from the prior year.
  • EBT reached -$26.6 million in Q4 2025 per URGN's latest filing, up from -$34.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$21.9 million in Q3 2023 to a low of -$48.9 million in Q2 2025.
  • Average EBT over 5 years is -$29.7 million, with a median of -$27.7 million recorded in 2021.
  • Peak YoY movement for EBT: skyrocketed 32.74% in 2021, then tumbled 57.31% in 2024.
  • A 5-year view of EBT shows it stood at -$27.3 million in 2021, then dropped by 3.17% to -$28.2 million in 2022, then increased by 21.36% to -$22.2 million in 2023, then plummeted by 57.31% to -$34.9 million in 2024, then grew by 23.59% to -$26.6 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's EBT are -$26.6 million (Q4 2025), -$34.4 million (Q3 2025), and -$48.9 million (Q2 2025).